RNAZ Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

9.040

Open

8.960

VWAP

8.84

Vol

5.64K

Mkt Cap

8.54M

Low

8.710

Amount

49.84K

EV/EBITDA(TTM)

--

Total Shares

916.97K

EV

5.70M

EV/OCF(TTM)

--

P/S(TTM)

--

TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.

Show More

Events Timeline

(ET)

2026-03-03

08:10:00

TransCode Enters Exclusive License Agreement with Unleash

2026-02-05 (ET)

2026-02-05

08:10:00

TransCode Submits IND Amendment for TTX-MC138 Clinical Trial

2026-01-06 (ET)

2026-01-06

08:10:00

TransCode Therapeutics Publishes TTX-MC138 Research Findings

2025-12-12 (ET)

2025-12-12

16:20:00

Transcode Therapeutics Files $150M Mixed Securities Shelf

2025-12-11 (ET)

2025-12-11

08:20:00

TransCode and Quantum Leap Collaborate to Evaluate TTX-MC138

2025-10-14 (ET)

2025-10-14

08:12:02

Transcode Therapeutics' TTX-MC138 Meets Safety Milestone in Phase 1a Trial

2025-10-08 (ET)

2025-10-08

08:10:18

Transcode Therapeutics set to purchase Polynoma

2025-05-08 (ET)

2025-05-08

08:08:00

Transcode Therapeutics completes dosing of patients in Phase 1a cancer trial

2025-05-02 (ET)

2025-05-02

16:11:36

Transcode Therapeutics announces 1-for-28 reverse stock split

2025-05-01 (ET)

2025-05-01

09:06:25

Transcode Therapeutics' TTX-MC138 shows no toxicities in Phase 1a cancer trial

News

PRnewswire

03-03PRnewswire

TransCode Enters Exclusive License Agreement with Unleash Immuno Oncolytics

PRnewswire

02-23PRnewswire

TransCode Publishes Novel Tumor Immunotherapy Research

PRnewswire

01-06PRnewswire

TransCode Publishes TTX-MC138 Research for Glioblastoma Treatment

Newsfilter

01-06Newsfilter

TransCode's TTX-MC138 Significantly Extends Survival in Glioblastoma Mouse Models

PRnewswire

2025-12-22PRnewswire

TransCode Appoints Jack E. Stover to Board of Directors, Enhancing Leadership Experience

Newsfilter

2025-12-22Newsfilter

TransCode Appoints Jack E. Stover to Board, Enhancing Oncology Expertise

Valuation Metrics

The current forward P/E ratio for Transcode Therapeutics Inc (RNAZ.O) is -5.68, compared to its 5-year average forward P/E of -2.09. For a more detailed relative valuation and DCF analysis to assess Transcode Therapeutics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-2.09

Current PE

-5.68

Overvalued PE

0.52

Undervalued PE

-4.70

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

12.08

Current PS

54.28

Overvalued PS

36.41

Undervalued PS

-12.25

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

what stock averages a daily 5% gain

Intellectia · 195 candidates

Price Change Pct: >= $5.00

Ticker

Name

Market Cap$

Brand Engagement Network Inc

181.88M

Battalion Oil Corp

71.92M

Check Cap Ltd

25.74M

Smart Logistics Global Ltd

94.71M

Gauzy Ltd

26.05M

Solo Brands Inc

18.24M

Whales Holding RNAZ

Trading Trends

People Also Watch

Frequently Asked Questions

What is Transcode Therapeutics Inc (RNAZ) stock price today?

The current price of RNAZ is 8.78 USD — it has decreased -5.69

What is Transcode Therapeutics Inc (RNAZ)'s business?

TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.

What is the price predicton of RNAZ Stock?

Wall Street analysts forecast RNAZ stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for RNAZ is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Transcode Therapeutics Inc (RNAZ)'s revenue for the last quarter?

Transcode Therapeutics Inc revenue for the last quarter amounts to -4.54M USD, increased 110.78

What is Transcode Therapeutics Inc (RNAZ)'s earnings per share (EPS) for the last quarter?

Transcode Therapeutics Inc. EPS for the last quarter amounts to USD, decreased -100.00

How many employees does Transcode Therapeutics Inc (RNAZ). have?

Transcode Therapeutics Inc (RNAZ) has 7 emplpoyees as of March 20 2026.

What is Transcode Therapeutics Inc (RNAZ) market cap?

Today RNAZ has the market capitalization of 8.54M USD.